206 related articles for article (PubMed ID: 26122021)
1. Germline and somatic genetic predictors of pathological response in neoadjuvant settings of rectal and esophageal cancers: systematic review and meta-analysis.
Salnikova LE; Kolobkov DS
Pharmacogenomics J; 2016 Jun; 16(3):249-65. PubMed ID: 26122021
[TBL] [Abstract][Full Text] [Related]
2. KRAS and Combined KRAS/TP53 Mutations in Locally Advanced Rectal Cancer are Independently Associated with Decreased Response to Neoadjuvant Therapy.
Chow OS; Kuk D; Keskin M; Smith JJ; Camacho N; Pelossof R; Chen CT; Chen Z; Avila K; Weiser MR; Berger MF; Patil S; Bergsland E; Garcia-Aguilar J
Ann Surg Oncol; 2016 Aug; 23(8):2548-55. PubMed ID: 27020587
[TBL] [Abstract][Full Text] [Related]
3. Association of thymidylate synthase polymorphisms with the tumor response to preoperative chemoradiotherapy in rectal cancer: a systematic review and meta-analysis.
Yang YC; Wu GC; Jin L; Wang KL; Bai ZG; Wang J; Zhang ZT
Pharmacogenomics J; 2017 Jun; 17(3):265-273. PubMed ID: 27001118
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenetic analysis in neoadjuvant chemoradiation for rectal cancer: high incidence of somatic mutations and their relation with response.
Balboa E; Duran G; Lamas MJ; Gomez-Caamaño A; Celeiro-Muñoz C; Lopez R; Carracedo A; Barros F
Pharmacogenomics; 2010 Jun; 11(6):747-61. PubMed ID: 20504250
[TBL] [Abstract][Full Text] [Related]
5. Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer.
Wu X; Gu J; Wu TT; Swisher SG; Liao Z; Correa AM; Liu J; Etzel CJ; Amos CI; Huang M; Chiang SS; Milas L; Hittelman WN; Ajani JA
J Clin Oncol; 2006 Aug; 24(23):3789-98. PubMed ID: 16785472
[TBL] [Abstract][Full Text] [Related]
6. A systematic review and meta-analysis of somatic and germline DNA sequence biomarkers of esophageal cancer survival, therapy response and stage.
Findlay JM; Middleton MR; Tomlinson I
Ann Oncol; 2015 Apr; 26(4):624-644. PubMed ID: 25214541
[TBL] [Abstract][Full Text] [Related]
7. The biomarker TP53 divides patients with neoadjuvantly treated esophageal cancer into 2 subgroups with markedly different outcomes. A p53 Research Group study.
Kandioler D; Schoppmann SF; Zwrtek R; Kappel S; Wolf B; Mittlböck M; Kührer I; Hejna M; Pluschnig U; Ba-Ssalamah A; Wrba F; Zacherl J
J Thorac Cardiovasc Surg; 2014 Nov; 148(5):2280-6. PubMed ID: 25135238
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenetics Biomarkers and Their Specific Role in Neoadjuvant Chemoradiotherapy Treatments: An Exploratory Study on Rectal Cancer Patients.
Dreussi E; Cecchin E; Polesel J; Canzonieri V; Agostini M; Boso C; Belluco C; Buonadonna A; Lonardi S; Bergamo F; Gagno S; De Mattia E; Pucciarelli S; De Paoli A; Toffoli G
Int J Mol Sci; 2016 Sep; 17(9):. PubMed ID: 27608007
[TBL] [Abstract][Full Text] [Related]
9. X-ray cross-complementing group 1 and thymidylate synthase polymorphisms might predict response to chemoradiotherapy in rectal cancer patients.
Lamas MJ; Duran G; Gomez A; Balboa E; Anido U; Bernardez B; Rana-Diez P; Lopez R; Carracedo A; Barros F
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):138-44. PubMed ID: 21167658
[TBL] [Abstract][Full Text] [Related]
10. MTHFR C677T Polymorphism is Associated with Tumor Response to Preoperative Chemoradiotherapy: A Result Based on Previous Reports.
Zhao Y; Li X; Kong X
Med Sci Monit; 2015 Oct; 21():3068-76. PubMed ID: 26456456
[TBL] [Abstract][Full Text] [Related]
11. DNA repair gene and MTHFR gene polymorphisms as prognostic markers in locally advanced adenocarcinoma of the esophagus or stomach treated with cisplatin and 5-fluorouracil-based neoadjuvant chemotherapy.
Ott K; Rachakonda PS; Panzram B; Keller G; Lordick F; Becker K; Langer R; Buechler M; Hemminki K; Kumar R
Ann Surg Oncol; 2011 Sep; 18(9):2688-98. PubMed ID: 21347786
[TBL] [Abstract][Full Text] [Related]
12. Integrating
Ntavatzikos A; Spathis A; Patapis P; Machairas N; Peros G; Konstantoudakis S; Leventakou D; Panayiotides IG; Karakitsos P; Koumarianou A
World J Gastroenterol; 2017 Aug; 23(32):5913-5924. PubMed ID: 28932083
[TBL] [Abstract][Full Text] [Related]
13. TYMS, MTHFR, p53 and MDR1 gene polymorphisms in breast cancer patients treated with adjuvant therapy.
Henríquez-Hernández LA; Pérez LF; Hernández AG; de León AC; Díaz-Chico B; Rosales AM
Cancer Epidemiol; 2010 Aug; 34(4):490-3. PubMed ID: 20371218
[TBL] [Abstract][Full Text] [Related]
14. A haplotype of the methylenetetrahydrofolate reductase gene predicts poor tumor response in rectal cancer patients receiving preoperative chemoradiation.
Terrazzino S; Agostini M; Pucciarelli S; Pasetto LM; Friso ML; Ambrosi A; Lisi V; Leon A; Lise M; Nitti D
Pharmacogenet Genomics; 2006 Nov; 16(11):817-24. PubMed ID: 17047490
[TBL] [Abstract][Full Text] [Related]
15. Distribution of TYMS, MTHFR, p53 and MDR1 gene polymorphisms in patients with breast cancer treated with neoadjuvant chemotherapy.
Henríquez-Hernández LA; Murias-Rosales A; González-Hernández A; de León AC; Díaz-Chico N; Fernández-Pérez L
Cancer Epidemiol; 2010 Oct; 34(5):634-8. PubMed ID: 20638924
[TBL] [Abstract][Full Text] [Related]
16. Predicting response to neoadjuvant therapy in esophageal cancer with p53 genotyping: a fortune-teller's crystal ball or a viable prognostic tool?
Nason KS
J Thorac Cardiovasc Surg; 2014 Nov; 148(5):2286-7. PubMed ID: 25444198
[No Abstract] [Full Text] [Related]
17. Pharmacogenetic study in rectal cancer patients treated with preoperative chemoradiotherapy: polymorphisms in thymidylate synthase, epidermal growth factor receptor, GSTP1, and DNA repair genes.
Páez D; Salazar J; Paré L; Pertriz L; Targarona E; del Rio E; Barnadas A; Marcuello E; Baiget M
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1319-27. PubMed ID: 21570215
[TBL] [Abstract][Full Text] [Related]
18. Biomarkers for response to neoadjuvant chemoradiation for rectal cancer.
Kuremsky JG; Tepper JE; McLeod HL
Int J Radiat Oncol Biol Phys; 2009 Jul; 74(3):673-88. PubMed ID: 19480968
[TBL] [Abstract][Full Text] [Related]
19. Does neoadjuvant therapy alter KRAS and/or MSI results in rectal adenocarcinoma testing?
Ondrejka SL; Schaeffer DF; Jakubowski MA; Owen DA; Bronner MP
Am J Surg Pathol; 2011 Sep; 35(9):1327-30. PubMed ID: 21836482
[TBL] [Abstract][Full Text] [Related]
20. HER2 status in patients with residual rectal cancer after preoperative chemoradiotherapy: the relationship with molecular results and clinicopathologic features.
Park JS; Yoon G; Kim HJ; Park SY; Choi GS; Kang MK; Kim JG; Jang JS; Seo AN
Virchows Arch; 2018 Oct; 473(4):413-423. PubMed ID: 30056472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
